BIOTRONIK Advances in Leadless Pacing with New LivIQ System

Biotronik has launched a pivotal study to evaluate the LivIQ leadless pacemaker—a next-generation device aiming to improve atrioventricular (AV) synchrony through advanced far-field sensing. Initial implantations were successfully conducted in Japan. Dr. Kenji Ando praised the system's intuitive implantation process. Dr. Kengo Kusano noted its promising AV-synchrony performance.

The BIO-LivIQ study will enroll 325 patients across 60 sites globally. It aims to assess the pacemaker's safety, pacing performance, and potential impacts on patients' quality of life. This data supports global regulatory submissions.

LivIQ reflects BIOTRONIK's commitment to physiologic pacing, using cutting-edge sensing technology for reliable AV synchrony. Its design streamlines implantation, addressing concerns like infection risks linked to traditional pacemakers.